Multiple Myeloma section

Multiple Myeloma News & Features

Obesity Increases Risk for Transformation of MGUS to Multiple Myeloma

Obesity Increases Risk for Transformation of MGUS to Multiple Myeloma

Researchers sought to determine the influence of obesity on the transformation of MGUS, an asymptomatic plasma cell neoplasm, to multiple myeloma.

Racial Disparities Persist in Myeloma Treatment Use

Racial Disparities Persist in Myeloma Treatment Use

Investigators found black patients with multiple myeloma are less likely to use newer, more advanced treatments such as autologous HSCT or bortezumib, and explored factors contributing to this as well as the impact on this population.

Adding Bortezomib to Rd Improves PFS, OS in Newly Diagnosed Myeloma

Adding Bortezomib to Rd Improves PFS, OS in Newly Diagnosed Myeloma

Researchers investigated whether VRd, which has demonstrated significant efficacy in newly diagnosed multiple myeloma, would improve outcomes in patients with previously untreated myeloma who are not planned for immediate ASCT.

3-drug Regimen With Ricolinostat Active, Safe in Multiple Myeloma

3-drug Regimen With Ricolinostat Active, Safe in Multiple Myeloma

Researchers report on an evaluation of the safety and preliminary efficacy of the HDAC6-selective inhibitor ricolinostat in combination with standard proteasome inhibitor therapy for relapsed or refractory multiple myeloma.

Longer Dosing Interval of Zoledronic Acid May Be Acceptable for Bone Metastases

Longer Dosing Interval of Zoledronic Acid May Be Acceptable for Bone Metastases

Results from a phase 3 trial comparing a 12-week dosing interval with the standard 4-week dosing interval of zoledronic acid to reduce the incidence of skeletal-related events and pain in patients with bone metastases.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs